Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are leading causes of irreversible blindness among the elderly population in developed countries. Although being considered as different subtypes of a same disease, neovascular AMD and PCV have differences in clinical, epidemiological, therapeutic, and genetic profiles. Both AMD and PCV are complex diseases involving multiple genetic and environmental risk factors. Different genetic strategies have been adopted to discover associated genes and variants for neovascular AMD and PCV, including genome-wide association study (GWAS), next-generation sequencing (NGS) based sequence analysis, and candidate gene analyses. So far, a number of susceptible genes have been identified for AMD and/or PCV, such as CFH, ARMS2-HTRA1, C2-CFB-SKIV2L, C3, CETP, and FGD6. Although many of these genes are shared by AMD and PCV, some showed difference between them, such as ARMS2-HTRA1 and FGD6. Also, some of the genes showed ethnic diversities, such as the CFH p.Tyr402His variant. Further larger-scale genomic studies should be warranted to identify more susceptibility genes for AMD and, in particular, PCV among different populations, and differentiate the genetic architectures between neovascular AMD and PCV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.APO.0000656976.47696.7d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short-term fluctuation of intraocular pressure and influencing factors following intravitreal injection in patients with retinal vascular diseases.
Int J Ophthalmol
November 2024
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Institute of Ophthalmology and Visual Sciences, Beijing 100730, China.
Aim: To investigate the patterns of short-term intraocular pressure (IOP) fluctuations and identify the contributing factors following intravitreal injection in patients with retinal vascular diseases.
Methods: Totally 81 patients were enrolled in this case control study. Eyes were categorized into 7 groups, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), idiopathic choroidal neovascularization (CNV), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), macular edema secondary to branch (BVOME) and central (CVOME) retinal vein occlusion.
Submacular hemorrhage: My personal journey to the goal.
Graefes Arch Clin Exp Ophthalmol
October 2024
Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan.
Acute submacular hemorrhage (SMH) can be caused by various diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), and retinal arterial microaneurysm (RAM). The natural course of submacular hemorrhage is generally poor. Animal studies have suggested that the removal of subretinal hemorrhage may effectively reduce retinal damage caused by hemorrhage in humans and removal of submacular hemorrhage have been performed with limited visual outcomes.
View Article and Find Full Text PDFFactors Affecting Visual Acuity After Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration: A Multicenter Study in Japan.
J Clin Med
October 2024
Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Article Synopsis
- Anti-VEGF therapy is the main treatment for neovascular age-related macular degeneration (nvAMD), and this study investigates factors influencing visual outcomes for treated patients.
- Conducted in Japan with 182 elderly patients, the study examines how age, baseline vision, and eye conditions affect visual acuity after one year of treatment with ranibizumab or aflibercept.
- Key findings reveal that younger age, absence of intraretinal fluid and pigment epithelial detachment, and lack of smoking or diabetes history can lead to better visual prognosis in nvAMD patients.
Clinical utility of swept-source optical coherence tomography angiography for the diagnosis of exudative maculopathy.
Jpn J Ophthalmol
November 2024
Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Article Synopsis
- The study evaluates the effectiveness of swept-source optical coherence tomography angiography (SS-OCTA) in distinguishing various macular diseases without using indocyanine green angiography (ICGA).
- It involves a review of 63 eyes from patients with treatment-naive neovascular age-related macular degeneration (AMD) and finds that SS-OCTA accurately identifies conditions like nonpolypoidal macular neovascularization (MNV) and polypoidal choroidal vasculopathy (PCV) with high sensitivity and specificity.
- The results suggest that SS-OCTA can be a viable alternative to ICGA for diagnosing these macular diseases, offering a reliable method for ophthalmologists to make decisions.
Optical Coherence Tomography Characteristics for Differentiating Scars in Type 1 (Polypoidal Choroidal Vasculopathy (PCV)) and Type 2 (Classical) Macular Neovascularization (MNV) in Age-Related Macular Degeneration (AMD).
Cureus
June 2024
Department of Ophthalmology, Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, IND.
Article Synopsis
- The study investigated the use of optical coherence tomography (OCT) to distinguish between scar features in two types (type 1 and type 2) of macular neovascularization (MNV) associated with age-related macular degeneration (AMD).
- Medical records of 20 patients over 50 years old were analyzed, focusing on various OCT measurements, including outer retinal tubulations and retinal thickness, to compare the two MNV types.
- Results showed that type 2 MNV had thinner choroid and distinct features on OCT compared to type 1 MNV, which could aid ophthalmologists in making better treatment decisions for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!